MULTIPLE MYELOMA IN RELAPSE

This study tests a combination of three drugs (ixazomib, pomalidomide, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to see if this new mix can control the cancer and how safe it is. About 52 adults with relapsed …

This early-stage study is testing a new drug called HPN217 in about 100 people whose multiple myeloma has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also measure how the drug moves th…

This study tests whether a combination of three drugs (elotuzumab, pomalidomide, and dexamethasone) given after a second stem cell transplant can help people with multiple myeloma that has come back. The goal is to keep the cancer under control for as long as possible. The study …

This early-stage study tests a new type of CAR-T cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy, UF-KURE-BCMA, is made from a simple blood draw and has a shorter manufacturing time than standard CA…

This study tests a drug called elranatamab in 50 adults with multiple myeloma that has returned or stopped responding to at least three prior treatments. The goal is to see if the drug can make cancer undetectable in the bone marrow at 6 and 12 months. Researchers will also monit…

This study tests a personalized approach using the drug selinexor combined with other medications for people whose multiple myeloma has returned or stopped responding to treatment. 18 adults with active disease after at least one prior therapy will receive one of three drug combi…

This study looks at whether a health technology program called All4Cure helps people with multiple myeloma become more active in managing their health. About 200 participants will fill out surveys online to measure their confidence and ability to handle their care. The goal is to…